Published in Products

Tenpoint's YUVEZZI launches to the US commercial market

This is editorially independent content
3 min read

Tenpoint Therapeutics, Ltd.’s YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% has officially made its debut in the U.S. commercial market—just 2 months after the FDA’s approval.

Big news! Let’s start with the basics.

What it is: A proprietary, pupil-modulating and fixed-dose eye drop that reduces the pupil size to allow only centrally-focused rays to enter the eye.

How it’s doing this: Via two dual-agent active ingredients (see below) that work together to target two different but complementary mechanisms of action (MOA), offering rapid symptom relief and long-term disease management.

  • Brimonidine tartrate
  • Carbachol

Explain how these work together.

Check out this rundown on the unique properties associated with brimonidine tartrate (a highly-selective alpha-2 agonist) and carbachol (a cholinergic and miotic agent).

Hint: It involves a prolonged “pinhole effect” that reduces pupil size for near-visual acuity improvement and a longer duration of action.

Next up: dosing and timing on those effects.

YUVEZZI is formulated for once-daily (in each eye) topical instillation via a single-dose vial.

  • See here for recommendations if wearing contact lenses.

As for its effects: Miosis should kick in around 30 minutes following instillation.

  • The duration: Up to 10 hours.

Speaking of that duration … what’s the supporting data behind this?

That would be phase 3 clinical findings from two studies (BRIO I and BRIO II) that went above and beyond the FDA’s requirements for approval of a fixed-dose combination.

Check out this brief recap of that data.

And for a more detailed breakdown:

  • See here for more on the BRIO I outcomes.
  • See here for more on the BRIO II outcomes.

Now for a closer look at its prescribing information.

The full prescribing information (PI) can be viewed here.

  • For adverse reactions observed in those aforementioned clinical trials, see here.
  • For warnings and precautions, click here.
  • And for contraindications, click here.

So! How can patients get a hold of this?

For qualifying patients (considering YUVEZZI is prescription-based), the drop is available directly via two options:

  • PHILRx (a national mail-order specialty pharmacy partner)
  • Retail pharmacies (see here for varying pricing)